Precision BioSciences Inc
PBS0
Company Profile
Business description
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Contact
302 East Pettigrew Street
Dibrell Building, Suite A-100
DurhamNC27701
USAT: +1 919 314-5512
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
68
Stocks News & Analysis
stocks
Strong guidance from undervalued ASX share
Shares surged after the announcement of first half fiscal 2026 guidance.
stocks
TSMC earnings: Refining guidance and expansion plans amid strong AI demand
We maintain our fair value estimate for TSMC stock.
stocks
Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio
Trying to make sense of a share caught up in irrational exuberance.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,168.70 | 33.00 | 0.36% |
| CAC 40 | 8,287.74 | 25.04 | 0.30% |
| DAX 40 | 24,235.14 | 80.67 | 0.33% |
| Dow JONES (US) | 48,578.72 | 115.00 | 0.24% |
| FTSE 100 | 10,574.49 | 15.50 | -0.15% |
| HKSE | 26,160.33 | 233.93 | -0.89% |
| NASDAQ | 24,102.70 | 86.69 | 0.36% |
| Nikkei 225 | 58,475.90 | 1,042.44 | -1.75% |
| NZX 50 Index | 12,905.67 | 160.39 | -1.23% |
| S&P 500 | 7,041.28 | 18.33 | 0.26% |
| S&P/ASX 200 | 8,946.90 | 36.80 | 0.41% |
| SSE Composite Index | 4,051.43 | 4.12 | -0.10% |